Fillers, especially hyaluronic acid ones, possess a plethora of beauty enhancing capabilities—they can lift, augment, and plump deficient areas for a more streamlined and defined visage. And with all the options available at the doctor’s office today, finding one that can check off every box on the list isn’t like finding a needle in a haystack. Yes, they all differ. And, yes, they come with different price tags and nuances. But the newest hyaluronic acid-based filler offers a big advantage over the some of the most tried-and-true injectables out there—it doesn’t cause nearly as much post-injection swelling.
Revanesse Versa, which received FDA approval in 2017 and launched in January 2018, uses a special highly controlled wet milling technology, which, according to Nashville, TN dermatologist Michael Gold, MD is basically the manufacturing process behind the gel. “There are a series of screens that the gel is pressed through which results in a uniform particle shape, size, and smoother solution.” Besides being well balanced and having less surface area, another benefit to the spherical molecules in Versa is less swelling. In clinical trials, Versa was shown to produce less swelling than other fillers, which can cause 24% more swelling—and less swelling equals less downtime, a big plus to patients. “In theory, the small, uniform, spherical particles promote optimal integration into the tissue, resulting in the body being less likely to recognize it as a foreign substance,” says Dr. Gold.
Considered the ‘microbrewery brand of aesthetic fillers’, Revanesse Versa is tested in-house before distribution, and to further ensure quality control, every syringe is individually inspected to make sure that it is safe and effective. The brand believes that small patch production ensures a high standard of quality and fresh products.
Priced less than its competitors, Versa treats moderate to severe lines and wrinkles and, according to Dr. Gold, lasts as long as every other hyaluronic acid filler when injected properly in the right patient for the right indication. One million syringes have been sold worldwide to date with no reported cases of nodules or granulomas—a huge coup for a new filler.